公开(公告)号：US20230048658A1

公开(公告)日：2023-02-16

申请号：US17825793

申请日：2022-05-26

Applicant: AMGEN INC.

Inventor： Trent P. MUNRO ,  Neeraj Jagdish AGRAWAL ,  Kristine M. DARIS

IPC: C07K16/18 ,  C12N15/65 ,  C12N15/67 ,  C07K16/06 ,  C12N15/85

Abstract: This invention relates to the general field of recombinant expression of polypeptides in animal cell culture. More specifically, the invention concerns improved selection of cells transfected with recombinantly engineered vectors designed to express polypeptides, in particular heteromultimeric polypeptides.

公开(公告)号：US20220363770A1

公开(公告)日：2022-11-17

申请号：US17621189

申请日：2020-06-26

Applicant: AMGEN INC.

Inventor： Irwin CHEN ,  Su CHONG ,  Fernando GARCES ,  Mark Leo MICHAELS ,  Christopher MOHR ,  Kenneth William WALKER ,  Zhulun WANG ,  Neeraj Jagdish AGRAWAL ,  Bryna FUCHSLOCHER ,  Kevin GRAHAM ,  Agnes Eva HAMBURGER ,  Derek E. PIPER ,  Cen XU

IPC: C07K16/28 ,  C07K16/46

Abstract: The present invention relates to antagonist antibodies of the human calcitonin gene-related peptide (CGRP) receptor as well as bispecific antigen binding proteins derived from the anti-CGRP antibodies that bind to and inhibit both the human CGRP receptor and another target, such as the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) receptor. Pharmaceutical compositions comprising the anti-CGRP receptor antibodies and bispecific antigen binding proteins as well as methods for producing them are also disclosed. Methods of using the anti-CGRP receptor antibodies and bispecific antigen binding proteins to ameliorate, treat, or prevent conditions associated with the CGRP and PAC1 receptors, such as chronic pain, migraine, and cluster headache, are also described.

公开(公告)号：US20220195022A1

公开(公告)日：2022-06-23

申请号：US17558032

申请日：2021-12-21

Applicant: AMGEN INC.

Inventor： Neeraj Jagdish AGRAWAL ,  Irwin CHEN ,  Su CHONG ,  Bryna FUCHSLOCHER ,  Kevin GRAHAM ,  Agnes Eva HAMBURGER ,  Mark Leo MICHAELS ,  Christopher MOHR ,  Derek E. PIPER ,  Kenneth William WALKER ,  Zhulun WANG ,  Cen XU

IPC: C07K16/18 ,  C07K16/28 ,  A61P25/06 ,  A61K38/22

Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

公开(公告)号：US20200048367A1

公开(公告)日：2020-02-13

申请号：US16607673

申请日：2018-04-27

Applicant: AMGEN INC.

Inventor： Neeraj Jagdish AGRAWAL ,  Pavan GHATTYVENKATAKRISHNA ,  Sekhar KANAPURAM ,  Christopher James SLOEY

IPC: C07K16/40 ,  A61K38/05 ,  A61K31/198 ,  A61K31/4172 ,  A61K31/401 ,  A61K47/26 ,  A61K9/08 ,  A61K9/19

Abstract: Provided herein are excipients capable of effectively reducing the viscosity of polypeptide (e.g., therapeutic polypeptide) formulations. The viscosity reducing excipients are dipeptides containing arginine at the carboxy terminus and N-acetylated serine or N-acetylated proline at the N-terminus. Glutamate-arginine is also disclosed as a viscosity-reducing dipeptide. Among the disclosed methods, methods of reducing the viscosities of such formulations are also provided.